Core Viewpoint - Heilongjiang Province's Public Resource Trading Center has published the credit evaluation results for pharmaceutical pricing and procurement, highlighting that China National Pharmaceutical Group Guorui Pharmaceutical Co., Ltd. has been rated as "seriously untrustworthy" due to violations of good faith practices [1][2]. Group 1: Company Information - China National Pharmaceutical Group Guorui Pharmaceutical Co., Ltd. was originally known as Huainan Sixth Pharmaceutical Factory, established in 1986, and became part of China National Pharmaceutical Group in 1998 [2]. - The company is a significant industrial strategic development base for China National Pharmaceutical Group [2]. Group 2: Products Involved - The serious untrustworthiness rating involves two products: injectable cefoperazone sodium and injectable betahistine hydrochloride [2]. - Injectable betahistine hydrochloride is a key product for the company and is noted as a unique product in the country [2]. Group 3: Evaluation Results - The credit evaluation results indicate that the serious untrustworthiness rating for the company became effective on May 30, 2025 [2].

Core Insights - The National Medical Products Administration (NMPA) approved 39 drug applications, including 37 supplementary applications and 2 re-registrations, highlighting the ongoing regulatory activity in the pharmaceutical sector [1] - Betahistine, a drug commonly used for treating vertigo, has seen significant market growth, with its market size increasing from 292 million to 5.925 billion from 2016 to 2023, indicating strong demand and development potential [3] - The injection form of Betahistine dominates the hospital market, accounting for over 70% of the market share, with sales of the hydrochloride injection reaching 3.271 billion in 2023 [5] Market Overview - The hospital terminal market for Betahistine is rapidly expanding, with the injection form being the most popular, representing 55.23% of total sales [5] - The top three companies in the Betahistine market are Shijiazhuang Fourth Pharmaceutical, China National Pharmaceutical Group, and Eisai, with market shares of 27.14%, 23.69%, and a significant position respectively [7] - There are currently 13 companies holding production licenses for Betahistine hydrochloride injection, indicating a competitive landscape [9] Regulatory and Product Information - Betahistine hydrochloride injection and its injectable form are classified as Category B drugs under the medical insurance system, with no reference preparations available for evaluation [10] - The tablet form of Betahistine is included in the National Essential Medicines List, with 23 production licenses held by 16 manufacturers, of which 4 have passed evaluations [10]